Semi-Annual Report — FY2026 H1
What PeptiDream Inc. reported for the period from 2026-01-01 to 2026-12-31.
Filed 2026-08-12View the original on EDINET
How much it says
46Typical
What moved here
9named for the first time
Its own wording
36terms
Which filing this is
35/ 35newest
No officer data yetThis company's filings have not been read for officers yet. Nothing is missing from the filings — the roster simply has not been extracted.
The gist
During the interim consolidated accounting period, the group recorded an operating loss, while the refinancing of the syndicated loan agreement was executed on 31 March 2026. Management determined that no material uncertainty existed regarding the going-concern assumption. The filing also describes progress in the Radiopharmaceutical Business and the Drug Discovery and Development Business.
Komori's summary of this document, not the document's own words.46Typical
How much this filing saysA weighted roll-up of 11 rubric dimensions, each scored from a fixed set of questions asked against this filing — built only from the 37 this document could answer. It measures how specific the disclosure is, not whether the company is doing well. Derived from the data, not editorial.
64
Detailed
38
Thin
28
Almost nothing
75
Very detailed
15
Almost nothing
53
Typical
27
Almost nothing
100
Very detailed
0
Almost nothing
55
Typical
50
Typical
R&D spend26億円Money spent making new things.
Cash left overNot disclosedThis document does not carry the figure.
Spent on equipment5億円Plants, machines — things meant to last.
EmployeesNot disclosedThis document does not carry the figure.
How to read this page
This is not the documentIt is Komori's reading of the filing submitted to EDINET. The original is linked above.
The score is not a verdictIt measures how specific the disclosure is. It says nothing about results or where the share price goes.
When it updatesContent lands once the filing has been read through. Right after submission, the summary can still be empty.